As the COVID 19 pandemic evolves, concerns about fungal co-infections and superinfections are increasing, mainly towards invasive pulmonary aspergillosis (IPA), which increases significantly the risk of mortality in these patients, thus requiring early detection and diagnosis for better treatment efficiency. We’re describing the case of a young, non-immunocompromised patient with SARS COV 2 infection, who developed an IPA due to Aspergillus flavus.